Zydus Cadila‘s Covid-19 vaccine ZyCoV-D is getting a nod for emergency use in India by this week. Union Health Minister Mansukh Mandaviya in the Rajya Sabha had said, “The government assumes that by October-November, four more Indian pharma companies will start production of vaccines which will help to reach the demand of vaccines, Biological E and Novartis vaccines will also be available in the coming months, and Zydus Cadila will soon get an emergency use permission from the Expert Committee.”
- Stocks Under F&O Ban: IndusInd Bank
- Dozee Secures $8 Mn to Boost Global Expansion
- Delhi Govt Allocates Rs 2,144 Crore for Ayushman Bharat in First Budget
- India Considers Tariff Reductions on $23 Billion in US Imports to Protect $66 Billion in Exports
- Trump Announces 25% Additional Tariff on Venezuela Trade
Zydus Cadila had said before that it has appealed for emergency use authorisation (EUA) with the Drug Controller General of India (DCGI) for its vaccine ZyCoV-D. The pharma company has conducted the most extensive clinical trial in India, with over 50 centres. Zydus Cadila’s vaccine will be the sixth coronavirus vaccine approved in India by the drug regulator after Covishield, Covaxin, Sputnik V, Moderna and Johnson & Johnson (J&J).
